Red Light Holland Corp. reports developments in legal regulated botanical wellness, natural-product therapeutic research, and regulated consumer products. The Ontario-based company owns Filament Health Corp., a clinical-stage natural botanical therapeutics developer with GMP production capabilities, FDA regulatory engagement, a global clinical research footprint, and PEX010, a patented botanical research compound therapeutic candidate.
Company news commonly covers peer-reviewed clinical data, research-institution distribution of PEX010, exclusive licenses to trial data and related intellectual property, and R&D initiatives based on consensual data collection. Updates also address commercial activities in Europe and North America, including regulated consumer product sales in the Netherlands' legal market and home cultivation kits sold through B2B and direct-to-consumer channels.
Red Light Holland (OTCQB: TRUFF) announced that Filament Health has completed a shipment of its botanical psilocybin drug candidate PEX010 into the European Union, released via a European Qualified Person, to supply multiple independent investigator-led studies, including projects linked to Nantes University Hospital and Region Stockholm in collaboration with Karolinska Institutet.
According to Red Light Holland, Filament only supplies PEX010 and is not running these trials. PEX010 now supports over 80 academic and philanthropic studies worldwide, backed by a portfolio of 76 issued patents across 13 families acquired when Red Light Holland closed its Filament transaction on April 30, 2026.
Red Light Holland (OTCQB:TRUFF) announced that Filament Health has begun its largest-ever manufacturing run of PEX010, a standardized, patented natural psilocybin drug candidate. The run adds a new 0.5 mg dose to existing 1, 5 and 25 mg strengths, creating a 0.5–25 mg standardized range from a single, consistent drug product.
PEX010 is protected by an international patent portfolio, has a demonstrated 36‑month shelf life, and has been supplied to 80+ research studies worldwide. The new low dose targets real-world microdosing patterns and aims to support controlled clinical research. Red Light completed its acquisition of Filament and its 76 issued patents on April 30, 2026.
Red Light Holland (OTCQB: TRUFF) announced that wholly owned subsidiary Filament Health signed an agreement with ARQ National Psychotrauma Centre in the Netherlands to supply its patented botanical psilocybin drug candidate PEX010 for a pilot feasibility study in military veterans with posttraumatic stress disorder (PTSD).
PEX010 will serve as the investigational drug product. According to Red Light Holland, PEX010 has been supplied to more than 80 academic and clinical studies worldwide, making it one of the most widely studied botanical psilocybin drug candidates in regulated clinical research.
Red Light Holland (OTCQB:TRUFF) reported that joint venture partner Magdalena Biosciences achieved positive preclinical results with a whole-leaf coca extract, its prescription drug candidate for post-GLP-1 weight loss management.
In a 20-day mouse study on a high-fat diet, the extract prevented weight gain without reducing food intake or increasing activity, supporting further development under FDA Botanical Guidance.
Red Light Holland (OTCQB:TRUFF), through wholly owned subsidiary Filament Health, signed an agreement with GHU Paris Psychiatrie & Neurosciences to supply its patented botanical psilocybin drug candidate PEX010 for the KETAPSYCHECOG academic study in France.
The randomized, double-blind, cross-over trial in healthy volunteers compares behavioral and neural effects of psilocybin and ketamine. The deal expands Filament’s clinical research footprint to France. PEX010 is already supplied to 80+ regulated studies worldwide.
Red Light Holland (OTCQB:TRUFF) announced that Filament Health’s standardized, patented natural psilocybin drug candidate PEX010 was selected by UCSF for a double-blind, randomized trial in healthy older adults with low well-being.
The study will assess safety, feasibility and effects on brain activity, neuroinflammatory biomarkers, and preclinical Alzheimer’s disease markers. PEX010, trusted in 80+ studies worldwide, is produced with proprietary extraction and stabilization methods. Red Light recently closed its acquisition of Filament, adding 76 issued patents across 15 families and PEX010 to its portfolio.
Red Light Holland (OTCQB: TRUFF) signed an addendum with Allu Therapeutics, expanding their New Zealand supply agreement to include Filament Health's GMP-compliant PEX010 botanical psilocybin drug candidate.
The deal adds Filament as a supplying affiliate and introduces a standardized microdose format of PEX010, already used at 70+ clinical research sites worldwide.
Red Light Holland (OTCQB: TRUFF) reported new clinical activity for its wholly owned subsidiary Filament Health’s botanical psilocybin candidate PEX010 following Filament’s acquisition.
PEX010 shipments now support Canadian academic studies in palliative care (Phase I/II and planned Phase 3), bipolar II treatment-resistant depression, and healthy adult mechanism research, while backing over 70 research studies worldwide and a 76‑patent portfolio.
Red Light Holland (CSE: TRIP, OTCQB: TRUFF) shareholders overwhelmingly approved a proposed corporate name change at the May 11, 2026 annual general and special meeting. Shareholders also approved auditor re-appointment, a share consolidation, and elected all nominated directors. The company announced CFO Keith Li's planned resignation and settled $735,874.22 of debt via issuing 18,396,855 common shares at $0.04 per share.
Red Light Holland (OTCQB: TRUFF) highlighted a JAMA Network Open randomized trial (published May 7, 2026) reporting a single synthetic dose of psilocybin reduced cocaine use versus active placebo through six months.
Filament Health holds an exclusive worldwide license to the trial data/IP and has Phase 2 authorization from the FDA and Health Canada for its botanical candidate PEX010.